TNFSF13B and Miyoshi myopathy: In recent years, compelling evidence has suggested that neutralizing APRIL or BAFF could diminish MM cell survival, revert the immunosuppressive phenotype on BCMA+ cells and reduce resistance of malignant cells to treatment, regardless of the presence of protective stromal cells (266, 268–270).